A new research has demonstrated that it becomes easier for smokers to quit smoking if they receive constant behavioral support and medication from others.
The study showed that this approach can successfully translate to the "real world" and that a combination of the two treatments offers almost a threefold chance of success over attempts to quit without using a cessation aid.
Daniel Kotz, PhD, from the University of Maastricht in the Netherlands, said that randomized clinical trials had a high internal validity, but because they were conducted under very strict conditions, they did not reflect the real world in which these treatments were supposed to be used and they therefore conducted a study to compare the various smoking cessation methods in the real world.
Investigators conducted a prospective cohort study in a random sample of 1,560 adult smokers who took part in an English national household survey between November 2006 and March 2012.
The study showed that a total of 23 percent reported not smoking at the end of the six-month period.
The investigators found that smokers who used a combination of specialist behavioral support and medication in their quit attempts reported higher levels of urges to smoke than did smokers who tried to quit unaided. After adjusting for this, they found smokers using the combination approach had almost three times the odds of success than did those who used neither medication nor behavioral support.
A combination of prescription medication along with limited behavioral support was also more effective than unaided quitting. They found however that smokers who bought nicotine replacement therapy (NRT) over the counter with no behavioral support had a reduced success rate.
J. Taylor Hays, MD, Director of the Mayo Clinic Nicotine Dependence Center in Rochester, Minnesota, said that tobacco use continued to be prevalent and deadly in the United States and worldwide.
Further, smoking cessation was one of the most important health behavior changes that they could encourage in their patients.
The study is published in Mayo Clinic Proceedings.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
